Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Fri, 09th Jul 2021 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Cambridge Cognition Holdings PLC, up 8.1% at 177.8 pence, 12-month range 35.1p-188p. Wins GBP1 million contract as cognitive assessment partner for a late phase cancer trial. Revenue from the contract is expected to be recognised over the next six years. "This is the second contract for a top ten pharmaceutical company with a strong pipeline of oncology products," the digital neuroscience company notes.

----------

Open Orphan, up 7.4% at 26.85p, 12-month range 11.5p-48p. Subsidiary hVIVO signs "significant" contract with AIM ImmunoTech Inc to test its antiviral candidate, Ampligen, using both the human Rhinovirus HRV and Influenza human challenge study models as part of a single study. This antiviral study will be conducted by hVIVO. The pharmaceutical services firm expects majority of revenue from the contract to be recognised in the current financial year. "As previously confirmed to the market, our London facilities are comprehensively prebooked throughout this year and into next year. As such, I am also delighted to confirm that we were solidly Ebitda profitable in H1 2021 and we remain on target for a profitable and successful 2021," says Open Orphan Executive Chair Cathal Friel.

----------

AIM - LOSERS

----------

Evgen Pharma PLC, down 30% at 5.19p, 12-month range 4.22p-15.76p. The clinical stage drug development company is "surprised and disappointed" after being informed that independent data management committee concludes analyses of SFX-01 in Star Covid-19 study did not meet the interim futility hurdle required to continue the study, and that active treatment would not be likely to show an overall statistically significant improvement. Recruitment into trial to be halted. "We are surprised and disappointed by these findings given the strong preclinical hypothesis surrounding sulforaphane as an Nrf2 activator with potential direct antiviral properties," says Chief Executive Huw Jones.

----------

Empyrean Energy PLC, down 24% at 6.43p, 12-month range 3.05p-9p. The oil and gas development company raises GBP5.0 million via placing of 83.7 million shares at price of 6.0p each. "Funds raised under this placing will primarily be used to secure a suitable drilling rig and order long lead items and for the Company's general working capital requirements as it prepares to drill the Jade prospect at its 100% owned Block 29/11 license in China, scheduled for late 2021," it says.

----------

Ilika PLC, down 24% at 153p, 12-month range 56.4p-285p. The advanced solid-state battery company plans placing of up to 12.8 million shares at price of 140p each to raise GBP18.0 million. Also intends to raise up to further GBP3.7 million through open offer, and will also make retail offer for up to GBP3.0 million via PrimaryBid. In total, eyes raising total gross proceeds of GBP24.7 million. "The net proceeds of the capital raising are expected to support the development of Ilika's solid-state electric vehicle pouch cells through its Goliath programme until the programme reaches and exceeds Lithium Ion Battery equivalence," it says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2021 11:32

Open Orphan subsidiary secures contract renewal with 'major' pharmaceutical client

(Sharecast News) - Contract research organisation Open Orphan said on Monday that its Venn Life Sciences subsidiary had signed a contract renewal with an unnamed "major global pharmaceutical client" worth £1.5m over a two-year period.

Read more
13 Oct 2021 13:25

EXECUTIVE CHANGES: Halfords hires CFO; new Pendragon, Versarien chairs

EXECUTIVE CHANGES: Halfords hires CFO; new Pendragon, Versarien chairs

Read more
20 Sep 2021 14:30

Open Orphan signs £5.7m contract with biotech specialist

(Sharecast News) - Clinical research organisation Open Orphan announced on Monday that its subsidiary hVIVO has signed a £5.7m contract with a specialist biotechnology company developing therapeutics for respiratory viral infections, to test its antiviral product using the hVIVO Influenza human challenge study model.

Read more
20 Sep 2021 12:02

TRADING UPDATES: Christie Group and Open Orphan swing to profit

TRADING UPDATES: Christie Group and Open Orphan swing to profit

Read more
13 Sep 2021 16:11

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
7 Sep 2021 18:16

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

TRADING UPDATES: Victoria growth continues; Renew to beat consensus

Read more
7 Sep 2021 14:59

TRADING UPDATES: Marlowe buys Santia; Gaming Realms notes new launch

TRADING UPDATES: Marlowe buys Santia; Gaming Realms notes new launch

Read more
24 Aug 2021 11:41

AIM WINNERS & LOSERS: Open Orphan rises on asthma study contract win

AIM WINNERS & LOSERS: Open Orphan rises on asthma study contract win

Read more
24 Aug 2021 09:31

Open Orphan shares lift on GBP8.1 million asthma study contract win

Open Orphan shares lift on GBP8.1 million asthma study contract win

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
22 Jul 2021 10:49

AIM WINNERS & LOSERS: Restore rises as it rebuffs Marlowe approach

AIM WINNERS & LOSERS: Restore rises as it rebuffs Marlowe approach

Read more
14 Jul 2021 16:15

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
14 Jul 2021 15:07

IN BRIEF: Open Orphan study grows, spinoff worth GBP50 million at IPO

IN BRIEF: Open Orphan study grows, spinoff worth GBP50 million at IPO

Read more
14 Jul 2021 15:01

IN BRIEF: Open Orphan team invests GBP350,000 as spin-off set to debut

IN BRIEF: Open Orphan team invests GBP350,000 as spin-off set to debut

Read more
14 Jul 2021 09:10

Open Orphan secures €900,000 contract with existing customer

(Sharecast News) - Pharmaceutical services company Open Orphan has secured a new contract win with an unnamed existing customer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.